Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection
Tóm tắt
The neurofilament is a major structural component of myelinated axons. Increased cerebrospinal fluid (CSF) concentrations of the light chain of the neurofilament protein (NFL) can serve as a sensitive indicator of central nervous system (CNS) injury. To assess whether interrupting antiretroviral treatment of HIV infection might have a deleterious effect on the CNS, we measured NFL levels in HIV-infected subjects interrupting therapy.
We identified subjects who had CSF HIV RNA concentrations below 50 copies/mL at the time combination antiretroviral therapy was interrupted, and for whom CSF samples were available before and after the interruption.
A total of 8 subjects were studied. The median (range) CSF NFL level at baseline was <125 (<125–220) ng/L (normal <250 ng/L). All 8 subjects exhibited an increase in CSF and plasma HIV RNA after stopping therapy, accompanied by intrathecal immunoactivation as evidenced by CSF lymphocytic pleocytosis (7/8 patients) and increased CSF neopterin concentration (5/6 patients). Three subjects showed a consistent increase in CSF NFL, rising from <125 ng/L to a maximum of 880 (at day 148), 1,010 (day 58) and 10,930 ng/L (day 101). None exhibited new neurological symptoms or signs, or experienced functional deterioration during the period off treatment; of 5 who underwent brief quantitative neurological testing, none showed worsening performance.
These findings suggest that resurgence of active HIV replication may result in measurable, albeit subclinical, CNS injury. Further studies are needed to define the frequency and pathobiological importance of the increase in CSF NFL.
Từ khóa
Tài liệu tham khảo
Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003, 362 (9377): 22-29. 10.1016/S0140-6736(03)13802-0
d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J: Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004, 55 (3): 320-328. 10.1002/ana.10827
Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet. 2000, 356 (9239): 1423-1430. 10.1016/S0140-6736(00)02854-3
Lori F, Lisziewicz J: Structured treatment interruptions for the management of HIV infection. Jama. 2001, 286 (23): 2981-2987. 10.1001/jama.286.23.2981
Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996, 67: 2013-2018.
Norgren N, Rosengren L, Stigbrand T: Elevated neurofilament levels in neurological diseases. Brain Res. 2003, 987 (1): 25-31. 10.1016/S0006-8993(03)03219-0
Blennow M, Savman K, Ilves P, Thoresen M, Rosengren L: Brain-specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr. 2001, 90 (10): 1171-1175. 10.1080/080352501317061594
Rosen H, Karlsson JE, Rosengren L: CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J Neurol Sci. 2004, 221 (1-2): 19-24. 10.1016/j.jns.2004.03.003
Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M: Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004, 63 (9): 1586-1590.
Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J: Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003, 61 (12): 1720-1725.
Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A: Neurofilament protein levels in CSF are increased in dementia. Neurology. 1999, 52 (5): 1090-1093.
Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A: Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001, 66 (3): 510-516. 10.1002/jnr.1242
Van Geel WJ, Rosengren LE, Verbeek MM: An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods. 2005, 296 (1-2): 179-185. 10.1016/j.jim.2004.11.015
Norgren N, Karlsson JE, Rosengren L, Stigbrand T: Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics. 2002, 21 (1): 53-59. 10.1089/15368590252917647
Hagberg L, Fuchs D, Rosengren L, Gisslen M: Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol. 2000, 102: 51-55. 10.1016/S0165-5728(99)00150-2
Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG: Cerebrospinal fluid response to structured treatment interruption after virological failure. Aids. 2001, 15 (10): 1251-1259. 10.1097/00002030-200107060-00006
Price RW, Deeks SG: Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. J Neurovirol. 2004, 10 Suppl 1: 44-51. 10.1080/13550280490268223
Hagberg L, Andersson LM, Abdulle S, Gisslen M: Clinical application of cerebrospinal fluid neopterin concentrations in HIV infection. Pteridines. 2004, 15: 102-106.
Tibbling G, Link H, Öhman S: Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977, 37: 385-390.
Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K: Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. Aids. 1999, 13 (13): 1677-1685. 10.1097/00002030-199909100-00011
Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD: Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003, 349 (9): 837-846. 10.1056/NEJMoa035103
Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL: Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A. 1987, 84 (10): 3472-3476.
Fischer M, Hafner R, Schneider C, Trkola A, Joos B, Joller H, Hirschel B, Weber R, Gunthard HF: HIV RNA in plasma rebounds within days during structured treatment interruptions. Aids. 2003, 17 (2): 195-199. 10.1097/00002030-200301240-00009
Huber C, Batchelor R, Fuchs D, Hause A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response-associated production of neopterin release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984, 160: 310-316. 10.1084/jem.160.1.310
Brew BJ, Dunbar N, Pemberton L, Kaldor J: Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis. 1996, 174: 294-298.
Gisslen M, Fuchs D, Svennerholm B, Hagberg L: Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999, 21 (4): 271-276.